Open Access

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway

  • Authors:
    • Liyan Du
    • Xiaomei Li
    • Linhong Zhen
    • Weiling Chen
    • Lingguang Mu
    • Yang Zhang
    • Ailin Song
  • View Affiliations

  • Published online on: March 16, 2018     https://doi.org/10.3892/mmr.2018.8769
  • Pages: 7163-7169
  • Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the most prevalent malignancies and the leading cause of cancer‑associated mortality in women worldwide and in China. Everolimus (C53H83NO14) is an efficient anti-cancer drug for breast cancer which targets mammalian target of rapamycin (mTOR). The present study investigated the inhibitory effects of everolimus on breast cancer cells and an MCF‑7‑bearing mouse model. The potential mechanism of the everolimus‑mediated decrease in growth and aggressiveness of breast cancer cells was reported. Results demonstrated that everolimus significantly inhibited breast cancer cell growth, migration and invasion. It was demonstrated that everolimus induced apoptosis through decreasing B cell lymphoma (Bcl)‑2 and Bcl‑w and increasing caspase‑3 and caspase‑8 expression levels in breast cancer cells. It was observed that everolimus decreased phosphoinositide 3‑kinase (PI3K), protein kinase B (AKT) and mTOR expression levels in breast cancer cells. Results additionally demonstrated that PI3 K overexpression prevented that everolimus‑mediated inhibition of growth and aggressiveness in MCF‑7 cells. In vivo assays demonstrated that everolimus treatment markedly inhibited tumor growth in the MCF‑7 bearing mouse model. Overall, these data indicate that everolimus inhibits growth and aggressiveness of breast cancer cells through the PI3K/AKT/mTOR signaling pathways, suggesting the PI3K/AKT/mTOR signaling pathway may act as a therapeutic target for the treatment of human cancer.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 17 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y and Song A: Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep 17: 7163-7169, 2018
APA
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., & Song, A. (2018). Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Molecular Medicine Reports, 17, 7163-7169. https://doi.org/10.3892/mmr.2018.8769
MLA
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., Song, A."Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway". Molecular Medicine Reports 17.5 (2018): 7163-7169.
Chicago
Du, L., Li, X., Zhen, L., Chen, W., Mu, L., Zhang, Y., Song, A."Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway". Molecular Medicine Reports 17, no. 5 (2018): 7163-7169. https://doi.org/10.3892/mmr.2018.8769